A Study of Imaging in Demyelinating Diseases

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Multiple SclerosisInflammatory Demyelinating Disease
Interventions
DRUG

C-11 ER176 Radiotracer

Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).

DRUG

C11 Pittsburgh Compound B

Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).

DIAGNOSTIC_TEST

PET/CT scan

Imaging of entire brain

DIAGNOSTIC_TEST

MRI

Magnetic Resonance Imaging of the Brain

Trial Locations (1)

55905

Mayo Clinic Minnesota, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05805839 - A Study of Imaging in Demyelinating Diseases | Biotech Hunter | Biotech Hunter